Please sign in to follow a disease.
Heart attack prevention: does opening a blocked artery save lives?
NCT ID NCT03392415
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study looks at whether opening a completely blocked heart artery with a procedure called PCI, on top of taking standard heart medications, helps people live longer and feel better compared to medications alone. About 2000 adults with stable heart disease and symptoms like chest pain or shortness of breath are taking part. The main goals are to see if the procedure reduces deaths and improves quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2018
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥1 CTO lesion amenable to PCI. * Stable and stabilized coronary artery disease * Symptoms (angina pectoris or shortness of breath) and/or signs of reversible perfusion defect by SPECT, PET or MR and/or angiographic/echocardiographic indication of reversible ischemia. * CTO lesion in a major coronary vessel supplying a significant myocardial territory (vessel diameter usually ≥3mm). Exclusion Criteria: * Expected survival \<1 year. * Renal failure on dialysis. * Stable non-CTO lesions treated within one month. * Declined informed consent. * Regarding CMR: allergy to contrast medium, severe obesity, claustrophobia and certain metallic implants
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Angina pectoris are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aalborg University Hospital
Aalborg, 9100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can AI read heart ultrasounds as well as trained sonographers?
- Can modern heart failure drugs reverse damage in three months?